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Summary. A series of new (S,S)-ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoate es-
ters has shown cytotoxic activity towards human leukemic cell lines. The aim of this 
study was to develop and validate a bioanalytical method for quantification of (S,S)-
O,O-diethyl-ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoate dihydrochlorides (DE-
EDCP) and its metabolite, substituted propanoic acid (EDCP), in mouse serum by ultra 
high-performance liquid chromatography–tandem mass spectrometry (UHPLC–
MS/MS). Structural analog, derivative of 1,3-propanediamine, was used as an internal 
standard (IS). Sample preparation employed protein precipitation by acetonitrile and 
subsequent centrifugation. Optimal UHPLC separation conditions were set to achieve 
simultaneous determination of both compounds in a short run time of 6 min. Addition-
ally, the selected reaction monitoring (SRM) mode developed in this method allowed a 
highly sensitive, accurate, and precise identification of compounds of interest. The lower 
limit of quantitation (LOQ) was 1.3 ng mL−1 for DE-EDCP and 0.3 μg mL−1 for EDCP. 
The calibration curves were linear over the concentration range of 1.3–26.7 ng mL−1 and 
0.3–6.7 μg mL−1 for DE-EDCP and EDCP, respectively. Precision (%CV) and accuracy 
(%RE) for DE-EDCP and EDCP ranged from 3.5% to 16.0% and from 1.8% to 14.4%, re-
spectively. 
The validation process was performed in accordance with the regulatory guid-
ance/guideline, and all of the obtained results met the established acceptance criteria. 
The newly developed and validated UHPLC–MS/MS method is rapid, sensitive, and se-
lective, and it can be successfully applied to drug monitoring in nonclinical studies. 
 
Key Words: UHPLC–MS/MS, protein precipitation sample preparation, (S,S)-
ethylenediamine-N,N′-di-2-(3-cyclohexyl) propanoic acid esters, cytotoxic activity, me-
tabolite 
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Introduction 
 
Novel ester derivatives of (S,S)-ethylenediamine-N,N′-di-2-(3-cyclohexyl) 
propanoic acid are toxic to leukemic cell lines [1]. It was demonstrated that 
methyl, ethyl, and n-propyl esters were toxic to HL-60, REH, MOLT-4, KG-
1, JVM-2, and K-562 leucemic cell lines, while the nonesterified compound 
and n-butyl ester were devoid of cytotoxic action. The ethyl ester exhibited 
the highest cytotoxic activity (IC50 in the range of 11–45 μM) [1].  
Platinum chemotherapeutic agents have been widely used in cancer 
treatment. Cisplatin was the first of the platinum-based chemotherapeutic 
agents and, therefore, has been extensively studied as an antitumor agent 
since the late 1960s [1]. It has revolutionized the treatment of various solid 
organ tumors [2], resulting in its widespread use among antineoplastic 
drugs [3]. 
It has been recently reported that octahedral platinum(IV) complexes 
with cyclohexyl-functionalized ethylenediamine-N,N′-diacetate-type lig-
ands affected various cancer cell lines with higher efficiency than the pro-
typical platinum-based antineoplastic drug cisplatin [1, 4]. 
The high efficiency and unusual mechanism of antineoplastic action of 
Pt(IV) complexes could be at least partly ascribed to their organic ligands 
designed to incorporate the ethylenediamine group, which is known for its 
positive contribution to the cytotoxicity of various compounds [1, 4]. In-
deed, the organic ligands alone exerted significant in vitro toxicity towards 
glioma, melanoma, and fibrosarcoma cell lines [1, 5].  
Although no direct correlation was observed between the cytotoxic po-
tency and the alkyl side-chain length of the compounds, the increase in al-
kyl side-chain length was apparently associated with the loss of activity of 
n-butyl ester [1]. 
(S,S)-O,O-diethyl-ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoate 
dihydrochlorides was chosen for further characterization since it exerted the 
strongest cytotoxic activity in HL-60 cell line. 
The observed cytotoxic effect in HL-60 cells was associated with an in-
crease in superoxide production and mitochondrial membrane depolariza-
tion, leading to apoptotic cell death characterized by phosphatidylserine ex-
ternalization and deoxyribonucleic acid (DNA) fragmentation in the ab-
sence of autophagic response [1]. 
It has also been observed that compounds with ester structure are 
prone to degradation by esterases and nonspecific pseudoesterases; there-
fore, the possibility of hydrolytic biotransformation to the carboxylic acid 
metabolites was speculated. This has to be taken into an account during 
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method development and validation as well as interpretation of further pre-
clinical pharmacokinetics studies. 
So far, the activity of the aforementioned compound has been investi-
gated exclusively in vitro. Hence, the need for rapid, sensitive, and selective 
bioanalytical method has arisen in order to proceed to the nonclinical stud-
ies involving the selected animal model. The aim of this study was to de-
velop and validate an ultra high-performance liquid chromatography–
tandem mass spectrometry (UHPLC–MS/MS) bioanalytical method for de-
termination of (S,S)-O,O-diethyl-ethylenediamine-N,N′-di-2-(3-cyclohexyl) 
propanoate dihydrochlorides and its hydrolytic metabolite in mouse serum. 
The structural analog, derivative of 1,3-propanediamine, was used as an in-
ternal standard (IS). The developed method is supposed to be integrated in 
future nonclinical studies and drug monitoring. 
 
 
Experimental 
 
Solvents and Chemicals 
 
(S,S)-O,O-diethyl-ethylenediamine-N,N′-di-2-(3-cyclohexyl) propanoate di-
hydrochlorides (DE-EDCP × 2HCl, C24H46O4N2Cl2; MW = 497.55 g mol−1), 
(S,S)-ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoic acid dihydrochlo-
rides (EDCP × 2HCl, C20H38O4N2Cl2; MW = 433.55 g mol−1), and internal 
standard (S,S)-O,O-dibutyl-1,3-propanediamine-N,N′-di-2-(3-cyclohexyl) 
propanoate dihydrochlorides (DB-PDCP × 2HCl, C29H52O4N2Cl2; MW = 
 567.67 g mol−1) were provided by Faculty of Chemistry, University of Bel-
grade, Serbia (S,S-enantiomers of mentioned substances were synthesized 
from enantiopure (S)-2-amino-3-cyclohexylpropanoic acid as starting mate-
rial) [5]. Acetonitrile, methanol, ethyl acetate, diethyl ether, triethanolamine, 
chloroform and trifluoroacetic acid (HPLC grade), ammonium acetate 
(CH3COONH4) and sodium fluoride (ACS grade) from Fluka (Sigma-
Aldrich Co.), and deionized water (Gen Pure Ultrapure, Germany) were 
used. Mouse serum was purchased from Sigma-Aldrich (Saint Louis, USA).   
 
 
Equipment 
 
Method development and validation were carried out on Thermo ACCELA 
(Thermo Scientific, Waltham, Massachusetts, USA) UHPLC system coupled 
to a triple quad Mass Spectrometer Thermo TSQ Quantum Access Max 
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(Thermo Scientific, Waltham, Massachusetts, USA) with a heated electros-
pray ionization (HESI) interface. A reverse-phase Thermo Scientific Hyper-
sil GOLD aQ column (100 × 2.1 mm, 1.9 μm, Thermo Scientific) and guard 
cartridge (Thermo Scientific Hypersil GOLD aQ, 10 mm L × 4 mm ID) were 
used. Solids were weighed using five-digit Mettler analytical balance (Met-
tler-Toledo International Inc., USA), and less sensitive weighting was per-
formed on Adventurer Pro analytical balance (OHAUS, USA). Sample 
preparation was done using Eppendorf 5417R microcentrifuge (Eppendorf, 
Germany). Solid-phase extraction (SPE), as an alternative sample prepara-
tion method, was performed using Strata X-C (Phenomenex, USA) and  
OASIS HLB (Waters, USA) cartridges. 
 
 
Software 
 
LogD tool in MarvinSketch 4.1.13 (ChemAxon, Budapest, Hungary) was 
used to calculate logD7.4 values of the investigated compounds. 
 
 
Preparation of Standard Solutions 
 
DE-EDCP, EDCP, and DB-PDCP (IS) were weighed from solid to an appro-
priate amount.  
DE-EDCP stock solution was prepared by dissolving 5 mg of solid  
DE-EDCP with methanol in a 50-mL volumetric flask in order to obtain the 
concentration of 0.1 mg mL−1. 
IS stock solution was prepared by dissolving 5 mg of solid DE-PDCP 
with methanol in a 50-mL volumetric flask. The concentration of the afore-
mentioned solution was 0.1 mg mL−1. 
Afterwards, the appropriate dilutions with methanol were made from 
IS stock solution to produce IS working solution (WS) of 10 ng mL−1.  
Another stock solution was made in methanol from 200 μL stock solu-
tion of DE-EDCP and appropriate amount of solid EDCP (5 mg) to obtain 
final concentrations of 0.2 μg mL−1 for DE-EDCP and 0.05 mg mL−1 for 
EDCP.  
Standard Preparation 
 
Stock solutions were diluted with methanol to obtain calibration solutions 
(CS) and four levels of quality control samples (QS). CS and QS were pre-
pared in 2 mL microcentrifuge tubes by spiking 150 μL of mouse serum 
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with various concentrations of DE-EDCP ranging 2–40 ng mL−1 and of 
EDCP ranging 0.5–10 μg mL−1. One hundred microliters of IS (10 ng mL−1 in 
methanol) and 750 mL acetonitrile (ACN) were added to each tested serum 
sample, and the microcentrifuge tubes were vortexed 1 min and then centri-
fuged (10 min, 25,000 rcf, 4 °C). Supernatants were transferred into glass vi-
als and analyzed by UHPLC–MS/MS thereafter.  
The serum concentrations of CS were 1.3, 3.3, 6.7, 10.0, 13.3, 20.0, and 
26.7 for DE-EDCP and 0.3, 0.8, 1.7, 2.5, 2.3, 5.0, and 6.7 for EDCP.  
The serum concentrations of QC samples were 1.3, 3.3, 10.0, and 20.0 
ng mL−1 and 0.3, 0.8, 2.5, and 5.0 μg mL−1 for DE-EDCP and EDCP, respec-
tively.  
All working and stock solutions were stored at 5 °C, in darkness. 
CS and QC were freshly prepared for each batch. 
 
 
Sample Preparation 
 
Fresh and thawed frozen sera containing enzyme-inhibitor sodium fluoride 
(40 mM) were used. 
 
Solid-Phase Extraction 
 
Initially, we tested the following SPE procedure: SPE column was activated 
with 1 mL of 5% triethanolamine–methanol (TEA–MeOH), followed by  
1 mL of 5% TEA–water; afterwards, SPE column was loaded with 50 μL of 
serum, 50 μL of methanol, 50 μL of IS, and 500 μL of 5% TEA–water; the elu-
tion step was performed with 500 µL of 5% TEA–MeOH, and the eluate was 
collected and analyzed by UHPLC–MS/MS. Afterwards, the same SPE pro-
cedure with 1% trifluoracetic acid–water instead of 5% TEA–water was 
tested. We have also tried out SPE procedure with serum being pretreated 
in the following manner: 50 μL of serum, 250 μL water, 250 μL 0.1 M ZnSO4, 
50 μL IS, and 450 μL of methanol were mixed together, vortexed for 30 s, 
and centrifuged for 5 min at 16,000 rcf. The supernatant was then used in 
the aforementioned SPE procedure with 5% TEA–water. All of the proce-
dures were tested on both Strata X-C (Phenomenex, USA) and OASIS HLB 
(Waters, USA) SPE cartridges. 
However, in all conducted procedures, the obtained recovery was up to 
50%. 
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Liquid-Liquid Extraction 
 
The following liquid–liquid extraction (LLE) procedure was also tested: 150 
µL of sample, 250 µL of water, 100 µL of methanol, 100 µL IS, 100 μL metha-
nol–water mixure (60:40, v/v), and 3 mL of ethyl acetate were mixed, briefly 
vortexed, and centrifugated for 15 min at 2500 rcf. Afterwards, the upper 
layer was transferred into the clean glass tube and evaporated under nitro-
gen at 40 °C. Dried debris was redissolved in 500 μL of methanol and vor-
texed prior to UHPLC–MS/MS analysis. Ethyl acetate, diethyl ether, chloro-
form, and ACN were also tested as extraction solvents. 
 
 
Protein Precipitation 
 
The same preparation procedure was applied for all samples, CS, and QS. 
One hundred and fifty microliters of mouse serum were transferred into 
clean 2 mL microcentrifuge tube. One hundred microliters of IS (10 ng mL−1 
in methanol), 100 μL of methanol, and 750 mL of ACN were added, and the 
microcentrifuge tubes were vortexed for 1 min. Samples were centrifuged 
(10 min, 25,000 rcf, 4 °C), and supernatants (300 μL) were transferred to 
clean glass autosampler vials for UHPLC–MS/MS analysis. 
 
 
Chromatographic and Mass Spectrometric Conditions 
 
DE-EDCP, EDCP, and IS were eluted using a mobile phase composed of 
ammonium acetate (5 mM)–trifluoroacetic acid (99.9:0.1, v/v) and metha-
nol–trifluoroacetic acid (99.9:0.1, v/v) according to the following gradient 
program: 50% buffer A and 50% buffer B were held from 0 to 1 min, and 
then, the buffer A was linearly decreased to 10% over 1.5 min and remained 
constant for 3.5 min when these analytes were eluted, followed by reequili-
bration to initial condition via a step gradient from 5 to 6 min. The flow rate 
was 0.3 mL min−1. 
Quantitation was achieved by MS–MS detection in positive ionization 
mode for DE-EDCP, EDCP, and IS. The MS operating conditions were op-
timized as follows: the spray voltage was 4500 V with a tube lens offset of 
107 V and skimmer offset of 0 V. The capillary temperature was set to 
300 °C. Nitrogen was used as the sheath gas (50 units) and auxiliary gas 
(10 units). Detection of the ions was performed in the selected reaction 
monitoring (SRM) mode using the following transitions of m/z 
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425.220 → 197.800 and 226.070 for DE-EDCP, m/z 369.256 → 152.130 and 
198.100 for EDCP, and m/z 495.339 → 166.034 and 268.062 for DB-PDCP 
(IS), respectively, with a scan time of 0.1 s per transition. TSQ Tune Software 
(Thermo Electron Corporation, Hemel Hepstead, UK) was used for the 
automatic optimization of tuning parameters. Data acquisition was per-
formed using Xcalibur 1.3 software (Thermo Electron Corporation, Hemel 
Hepstead, UK). Peak integration and calibrations were performed using LC 
Quan™ software (Version 2.5.6, Thermo Electron Corporation, Hemel 
Hempstead, UK). 
 
 
Validation of UHPLC–MS/MS Method 
 
The developed quantitative UHPLC–MS/MS method was validated by tak-
ing into account selectivity, linearity, accuracy, precision, limit of quantita-
tion (LOQ), recovery, matrix effects, and stability in accordance with the 
regulatory guidance/guideline [6, 7]. Thereafter, a validation was carried 
out for DE-EDCP and EDCP analysis in mouse serum samples. 
 
 
Selectivity 
 
The selectivity of the method was evaluated by analyzing six independent 
drug-free mouse serum samples with the corresponding spiked plasma at 
LOQ.   
Coeluting components should not be present in the amount greater 
than 20% of the analyte and 5% of the corresponding IS as seen by compar-
ing relevant peak areas. 
 
Linearity of calibration dependencies 
 
Calibration curves were generated to confirm the relationship between the 
peak area ratios and the concentration of DE-EDCP and EDCP, respectively, 
in the standard samples. Fresh calibration solutions (CS) were extracted and 
assayed as described above on three different days and in duplicate. Cali-
bration curves for DE-EDCP were represented by the plots of peak area ra-
tio (DE-EDCP/DB-PDCP) versus the nominal concentration of the DE-
EDCP in CS. Calibration curves for EDCP were represented by the plots of 
the peak area ratio (EDCP/DB-PDCP) versus the nominal concentration of 
the EDCP in CS. The coefficient of the correlation should exceed 0.99. 
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Accuracy and precision 
 
The accuracy and precision were evaluated using the spiked samples at four 
concentration levels of 1.3 ng mL−1 and 0.3 μg mL−1 (LOQ), 3.3 ng mL−1 and 
0.8 μg mL−1 (low), 10 ng mL−1 and 2.5 μg mL−1 (medium), and 20 ng mL−1 
and 5 μg mL−1 (high) for DE-EDCP and EDCP, respectively. The spiked 
samples were analyzed in six replicates on three different days. Assay accu-
racy was calculated as the relative error to the nominal concentration (%RE). 
Assay precision was calculated as the coefficient of variation (%CV). The ac-
ceptance criteria were set at within ±15% of the %RE except for the LOQ 
where it should be within ±20% and at <15% of the %CV except for the LOQ 
where it should be <20%. 
 
Limit of quantitation 
 
The lower limit of quantitation (LOQ), defined as the lowest concentration 
on the calibration curve, was evaluated by analyzing the samples prepared 
in six replicates on three consecutive days. 
The signal-to-noise ratio should be larger than 5. 
 
 
Recovery (%) 
 
The recovery of analyte in an assay is the detector response obtained from 
an amount of the analyte added to and extracted from the biological matrix, 
compared to the detector response obtained for the true concentration of the 
analyte in solvent. Recovery pertains to the extraction efficiency of an ana-
lytical method within the limits of variability. Recovery of the analyte need 
not be 100%, but the extent of recovery of an analyte and of internal stan-
dard should be consistent, precise, and reproducible [6]. 
Recovery experiments were performed by comparing the analytical re-
sults for extracted samples and four concentrations (LOQ, low, medium, 
and high) with unextracted standards that represent 100% recovery. 
The recovery was evaluated for DE-EDCP and EDCP at four concentra-
tion levels of 1.3 ng mL−1 and 0.3 μg mL−1 (LOQ), 3.3 ng mL−1 and  
0.8 μg mL−1 (low), 10 ng mL−1 and 2.5 μg mL−1 (medium), and 20 ng mL−1 
and 5 μg mL−1 (high) for DE-EDCP and EDCP, respectively. The peak area 
ratios obtained from extracted samples at the above mentioned concentra-
tions were compared with those of the corresponding unextracted standard 
solutions (LOQ, low, medium, and high). 
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Matrix effects 
 
Blank mouse serum was extracted and then spiked with analyte and IS to 
assess the matrix effect. The corresponding peak area ratios of the analyte to 
IS in spiked serum postextraction (A) at low and high QC levels were then 
compared with those of the corresponding standard samples (B) at equiva-
lent concentrations. The ratio A/B × 100% is defined as the matrix effect. 
 
 
Stability 
 
It was tested in vitro stability of stock and standard solutions. 
 
 
Stock solution stability 
 
The stability of DE-EDCP, EDCP, and IS in methanol was evaluated at room 
temperature, 5 °C, and −20 °C. Stock solutions with concentrations of 
100.0 μg mL−1 for IS and DE-EDCP and concentration of 50 μg mL−1 for 
EDCP were prepared in methanol. Three aliquots of each of the stock solu-
tions were kept at room temperature, 5 °C, and −20 °C, respectively, for  
7 days. After diluting the stored stock solutions in injection solvent to 
100.0 ng mL−1, the stability of DE-EDCP, EDCP, and IS was assessed by 
comparing the peak areas obtained from the stored stock solutions with 
peak areas of the freshly prepared stock solutions. For stock solution results 
to be acceptable, the percentage reference value should not exceed 15%. 
 
 
Standard solutions stability 
 
The stability of DE-EDCP, EDCP, and IS in methanol was evaluated at room 
temperature, 5 °C, and −20 °C. Standard solutions with concentrations of 
200 ng mL−1 for DE-EDCP, 50 μg mL−1 for EDCP, and 10 ng mL−1 for IS 
were prepared in methanol. Three aliquots of each of the standard solutions 
were kept at room temperature, 5 °C, and −20 °C, respectively, for 3 days. 
The stability of DE-EDCP, EDCP, and IS was assessed by comparing the 
peak areas obtained from the stored stock solutions with peak areas of the 
freshly prepared standard solutions. For stock solution results to be accept-
able, the percentage reference value should not exceed 15%. 
B.K. Tubić et al. 
 
244 
Autosampler stability of DE-EDCP, EDCP, and IS was determined at 
four low, medium, and high QC concentrations. Autosampler stability of 
extracted samples was determined by comparing DE-EDCP, EDCP, and 
DB-PDCP concentration in freshly prepared samples and samples kept in 
autosampler at 4 °C for 24 h. 
 
Results and Discussion 
 
Method Development 
 
The developed and validated bioanalytical method that has been presented 
in this article is a new ultra high-performance liquid chromatography–
electrospray ionization–tandem mass spectrometry (UHPLC–ESI–MS/MS) 
method for the quantification of recently synthesized substance DE-EDCP 
and its metabolite EDCP in biological material. The structures of DE-EDCP, 
EDCP, and DB-PDCP are given in Fig. 1. Since substances do not possess  
maximum absorption in the UV part of the spectrum, we have opted for the 
mass detector. Maximum absorption with molar absorptivity of DE-EDCP 
and DB-PDCP is λ = 209 nm (a = 0.127 dm3 cm−1 mol−1) and λ = 215 nm (a = 
0.085 dm3 cm−1 mol−1), respectively. As regards initial physicochemical 
characterization of DE-EDCP and EDCP, we found that the two compounds  
 
 
 
Fig. 1. Chemical structures of DE-EDCP, EDCP, and DB-PDCP 
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differ in polarity; logarithm values of the distribution coefficient (D) in  
octanol–water at pH 7.4 (log D7.4) were 4.04 and −1.8 for DE-EDCP and 
EDCP, respectively, and isoelectric point value for EDCP was 5.49 (by 
MarvinSketch 4.1.13).  
Using sodium-fluoride-coated blood collection tubes in preanalytical 
phase proved successful in achieving esterase inhibition [8].  
Internal standard DB-PDCP was selected according to structural simi-
larity (structural analog). A small number of drugs used in medicine have 
ethylenediamine structure. The compounds previously analyzed by a group 
of researchers led by T. Sabo were actually ligands of Pt-complexated ethyl-
enediamine and 1,3-propanediamine [9–12]. 
Extraction method from biological material was based on protein pre-
cipitation by addition of five volumes of ACN [13] and centrifugation at low 
temperature. Our preliminary exploration has shown that acetonitrile-
induced precipitation has provided higher extraction recovery and cleaner 
samples than methanol. Protein-binding property of DE-EDCP was over-
come by optimizing vortexing time to exactly 1 min since longer vortexing 
resulted in loss of linearity. 
While developing the extraction procedure, SPE was considered for ex-
tracting DE-EDCP from mouse serum. Although both basic and acidic 
washing and elution reagents as well as two different SPE columns were 
tested, each time, unsatisfactory extraction yields for both compounds (re-
covery was less than 50%) were obtained. We have also included protein 
precipitation procedure with 0.1 M ZnSO4 solution preceding the SPE ex-
traction, in order to improve the extraction yield. Nevertheless, it proved 
unsuccessful.  
We also tried to carry out the LLE using diethyl ether, chloroform, and 
ACN, but none of those solvents managed to achieve satisfying extraction 
yield of both DE-EDCP and EDCP in the same liquid phase because of the 
difference in polarity of the observed substances. In addition, the LLE 
method proved to be quite time-consuming.  
The mobile phase, composed of 5 mM CH3COONH4 with 0.1% 
trifluoroacetic acid and MeOH with 0.1% trifluoroacetic acid, was chosen 
since the investigated compounds and ethambutol both share the diethyl-
amine-based structure [14]. Excellent chromatographic separation in six-
minute run period was obtained by applying a suitable gradient. The ap-
pearance of the chromatogram is shown in Fig. 2. 
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Fig. 2. Appearance of chromatogram (chromatographic separation of DE-EDCP, EDCP, 
and DB-PDCP) 
 
 
Both compounds were quantified following the appropriate mass tran-
sitions for DE-EDCP (m/z 425.220 → 197.800, 226.070), EDCP (m/z 
369.256 → 152.130, 198.100), and DB-PDCP (m/z 495.339 → 166.034, 
268.062). Proposed SRM fragmentation patterns and structures are given in 
Figs. 3–5. 
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Fig. 3. The proposed SRM fragmentation patterns of DE-EDCP 
 
 
Fig. 4. The proposed SRM fragmentation patterns of EDCP 
B.K. Tubić et al. 
 
248 
 
 
Fig. 5. The proposed SRM fragmentation patterns of DB-PDCP 
 
 
In the MS–MS spectra, the most abundant daughter ions (m/z = 226 for 
DE-EDCP and m/z = 268 for DB-PDCP) resulted from loss of corresponding 
ester of 2-amino-3-cyclohexylpropanoic acid from only one side of mole-
cules (Figs. 3 and 5). The loss of corresponding alkoxy group from one side 
of both molecules and the loss of corresponding ester of 3-cyclo-
hexylpropanoic acid from other side of both molecules at the same time 
produced daughter ions m/z = 197 and m/z = 211 for DE-EDCP and  
DB-PDCP, respectively. The breaking of C–C bond inside of 1,3-pro-
panediamine chain in parent ion can be seen as specific fragmentation pat-
tern for DB-PDCP (Fig. 5) to form two ions (m/z = 254 and m/z = 168). The 
similar fragmentation pattern occurs both in DE-EDCP and EDCP but with 
additional cleavage of ethoxycarbonyl or carboxylic groups to form daugh-
ter ion m/z = 152 (Figs. 3 and 4). The daughter ions m/z = 351 and 
m/z = 323 are formed by only from the one side cleavage of ethoxycarbonyl 
and carboxylic groups in DE-EDCP and EDCP, respectively.  
 
Highly Sensitive UHPLC–MS/MS Method 
 
249 
The presented method was applied in real sample, in mice, and we 
found that EDCP exists as one of metabolites. 
The presented method of extraction and UHPLC–MS/MS analysis may 
be successfully applied for analyzing serum, plasma, liver, and brain ho-
mogenate for determining the preliminary pharmacokinetic profile of DE-
EDCP and EDCP in mice. 
 
 
Method Validation 
 
The developed bioanalytical method for DE-EDCP and EDCP in mouse se-
rum was validated for its selectivity, linearity of calibration dependencies, 
accuracy and precision, limit of quantitation, recovery, matrix effect, and 
stability. 
 
Selectivity 
 
The method was found to be highly selective for the analytes since no inter-
fering peaks from endogenous compounds were observed at the retention 
time for DE-EDCP and EDCP in any of the six independent blank serum ex-
tracts evaluated. 
 
Linearity of calibration dependencies 
 
The linear regressions of the peak area ratios versus concentration were fit-
ted over the concentration range in mouse serum of 1.3–26.7 ng mL−1 and 
0.3–6.7 μg mL−1 for DE-EDCP and EDCP, respectively. The typical equation 
of the calibration curves was as follows: DE-EDCP: y = 0.0461x + 0.0895, 
r = 0.9978; EDCP: y = 0.1527x + 0.0045, r = 0.9987 where y represents the 
peak area ratio of analyst to IS and x represents the concentration of the ana-
lyst in serum. The correlation coefficient (r) exceeded 0.99, showing a good 
linearity over the concentration range. 
 
 
Accuracy and precision 
 
Table I shows the results of the QC samples at four concentration levels ana-
lyzed in six replicates for DE-EDCP and EDCP, respectively. The precision 
(%CV) and the accuracy (%RE) ranged from 3.5% to 16.0% and from 1.8% to 
14.4%, respectively. 
B.K. Tubić et al. 
 
250 
Table I. The precision (%CV) and accuracy (%RE) for DE-EDCP and EDCP 
Compound 
Concentration 
(expected) 
ng mL−1 
Mean concentration
(measured) 
ng mL−1 
CV (%) RE (%) 
1.33 — LOQ 1.3 ± 0.6 15.99 3.0 
3.33 3.8 ± 1.0 13.68 12.6 
10.00 10.6 ± 0.4 2.25 6.3 
DE-EDCP 
20.00 20.4 ± 1.1 3.49 1.8 
0.33 — LOQ 0.4 ± 0.1 5.58 6.1 
0.83 0.8 ± 0.1 4.43 −2.4 
2.50 2.4 ± 0.2 5.32 −3.2 
EDCP 
5.00 4.3 ± 0.3 4.01 −14.4 
 
 
Limit of quantitation 
 
The lower limit of quantitation (LOQ) was 1.3 ng mL−1 for DE-EDCP and 0.3 
μg mL−1 for EDCP. The intra- and inter-relative standard deviations (RSD) 
were both less than 20%, and the %RE was within ±9.7% at LOQ level, 
which were within the accepted limits. 
 
 
Recovery % 
 
The recovery for DE-EDCP and for EDCP ranged from 90% to 99% and 
from 76% to 100%, respectively, through four concentration levels. The re-
covery for the IS was 98%. 
 
Matrix effect 
 
The calculated matrix effects were in the 95.5–108.2% range. Therefore, ion 
suppression or enhancement effect deriving from serum was negligible un-
der the current conditions. 
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Stability studies 
 
All the results showed that the analyte was stable under the conditions in 
which the stability assessment was performed: DE-EDCP, EDCP, and IS 
were stable in methanol in stock solutions at all storage temperatures (at 
room temperature, 5 °C, and −20 °C) for 7 days; DE-EDCP, EDCP, and IS 
were stable in methanol in standard solutions at all storage temperatures (at 
room temperature, ~5 °C, and −20 °C) for 3 days. 
DE-EDCP, EDCP, and IS were found to be stable in supernatants ob-
tained after sample preparation during 24-hour period spent in autosampler 
at 4 °C regardless the concentration. 
 
 
Conclusion 
 
The newly developed and validated ultra high-performance liquid chroma-
tography–electrospray ionization–tandem mass spectrometry (UHPLC–
MS/MS) is rapid and specific. Therefore, the observed method is sensitive, 
allowing determination of very low concentrations of DE-EDCP (LOQ was 
1.3 ng mL−1) and EDCP (LOQ was 0.3 μg mL−1) in mouse serum. The recov-
ery was in the range of 90% to 100%, respectively. The method may be suc-
cessfully applied to drug monitoring in nonclinical studies in selected ani-
mal model. 
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